Previous 10 | Next 10 |
Vascular Biogenics ( VBLT ) -78% after late-stage trial for ovarian cancer treatment fails ; cut to Neutral at HC Wainwright after trial failure sinks stock 79%. Adial Pharmaceuticals ( ADIL ) -28% as AD04 fails to best placebo in very heavy drinkers in t...
Revolution Medicines ( NASDAQ: RVMD ) has priced an upsized $230M common stock offering at $20 per share. The underwritten public offering is for 115M shares. Underwriters have the opportunity to purchase an additional 1.725M shares. The offering is expected to clo...
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the pricing of its underwritten public offering of 11,500,000 shares of common stock a...
Revolution Medicines ( NASDAQ: RVMD ) on Tuesday has initiated plans to raise up to $200M in primary stock offering. The biotech company intends to grant the underwriters an overallotment option to purchase up to an additional $30M shares. J.P. Morgan, Cowen and G...
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that it has commenced an underwritten public offering to sell up to $200 million of sh...
REDWOOD CITY, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Lorence Kim, M.D., to its board of directors. Dr. Kim has made sign...
Data on Amgen's Lumakras (sotorasib) in combination with Merck's ( NYSE: MRK ) Keytruda (pembrolizumab) and Roche's ( OTCQX:RHHBY ) Tecentriq (atezoliuzumab) will be released on Aug. 7 instead of this month, Reuters reported. Results will be released at the 20...
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRAS G12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise, elected to board of directors REDWOOD CITY, Calif., June 28, 2022 (GL...
REDWOOD CITY, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that the company will participate in the 43 rd Annual Goldman Sachs Global Healthc...
BofA Securities has initiated Revolution Medicines (NASDAQ:RVMD) at neutral saying that most of the precision oncology company's candidates still need validation. The firm has a $24 price target (~58% upside based on Thursday's close). Analyst Alex Stranahan highlighted that the company's pla...
News, Short Squeeze, Breakout and More Instantly...
Revolution Medicines Inc. Company Name:
RVMD Stock Symbol:
NASDAQ Market:
Revolution Medicines Inc. Website:
2024-07-24 09:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-14 06:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Original research published in Cancer Discovery reveals a RAS(ON) multi-selective inhibitor exhibited robust anti-tumor activity alone or in combination with a RAS(ON) G12C-selective inhibitor in preclinical models of difficult-to-treat KRAS-mutated non-small cell lung cancer (NSCLC) Re...